Abstract
Eculizumab in AQP4+ neuromyelitis optica spectrum disorder: 3 years of data from Japanese post-marketing surveillance
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
